Kailera Therapeutics Completed Obesity Trial Enrollment
The company has finished enrolling participants for its global Phase 3 clinical program testing ribupatide.
Updated on Sept. 30, 2026 in Weight Loss
Live Poll
Should medical treatments be the primary focus for managing obesity in the U.S.?
Kailera Therapeutics has completed enrollment for the KaiNETIC global Phase 3 clinical program, which evaluates the efficacy and safety of the ribupatide injection for treating obesity or overweight. The trials involve approximately 4,900 adults across more than 200 sites in eleven countries.
Why it matters
The KaiNETIC program represents a major effort to expand treatment options for patients managing weight through a dual GLP-1/GIP receptor agonist. Success in these trials could confirm the viability of ribupatide as a new standard for obesity care.
The study evaluates a weekly subcutaneous ribupatide injection at doses up to 10 mg over a 76-week period. Participants include 2,500 adults in KaiNETIC-1, 1,200 in KaiNETIC-2, and 1,200 in KaiNETIC-3.
The players
Kailera Therapeutics
This biopharmaceutical company focuses on developing innovative therapies and holds global rights to the ribupatide injection.
Hengrui
This pharmaceutical firm granted Kailera the exclusive rights to develop and commercialize ribupatide outside of Greater China.
The details
Ribupatide is a dual GLP-1/GIP receptor agonist administered via weekly subcutaneous injection, with study protocols requiring up to 24 weeks of dose titration followed by at least 52 weeks of maintenance. Kailera Therapeutics holds exclusive global development and commercialization rights outside of Greater China for the peptide.
Timeline
May 2024: Kailera acquired global rights for ribupatide.
September 30, 2026: The company announced the completion of trial enrollment.
First half 2027: Planned initiation of oral ribupatide Phase 3 trials.
Mid-2028: Expected release of topline data from the KaiNETIC clinical program.
The Big Picture
This program extends the development trajectory established by the broader GLP-1 receptor agonist drug class.
Patients may eventually gain access to a new once-weekly dual-action treatment option if these trials successfully demonstrate efficacy. However, the development remains in the clinical phase, meaning the drug is not yet available for current medical use.
The takeaway
The completion of enrollment marks a significant milestone in the multi-year path toward potential market approval for this new obesity treatment. Readers should note that clinical results are still several years away as researchers continue to monitor the long-term safety and efficacy of the drug.
What happens next
Kailera plans to initiate global Phase 3 trials for once-daily oral ribupatide in the first half of 2027, with topline data from the current KaiNETIC injections expected in mid-2028.
Further reading
For more on the current landscape of obesity research, visit the Weight Loss section.
Live Poll
Should medical treatments be the primary focus for managing obesity in the U.S.?
